89868-06-4

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINO-6-PHENYL-3(2H)-PYRIDAZINONE is used as a key intermediate in the synthesis of various organic compounds, particularly those with potential pharmaceutical applications. Its unique structure allows for the development of new drugs and therapeutic agents.
Used in Research Field:
4-AMINO-6-PHENYL-3(2H)-PYRIDAZINONE is used as a research compound for studying its potential biological activities and exploring its applications in medicinal chemistry. Further research and testing are needed to fully understand its properties and potential uses in drug discovery and development.

InChI:InChI=1/C10H9N3O/c11-8-6-9(12-13-10(8)14)7-4-2-1-3-5-7/h1-6H,(H2,11,12)(H,13,14)

Upstream product

• 87769-56-0 2,3-dihydro-3-oxo-6-phenyl-4-pyridazinecarboxamide 
• 2166-31-6 6-phenylpyridazin-3(2H)-one 
• 34753-27-0 ethyl 2,3-dihydro-3-oxo-6-phenyl-4-pyridazinecarboxylate 
• 64942-62-7 3,4-dichloro-6-phenylpyridazine 
• 98-86-2 acetophenone 
• 298-12-4 Glyoxilic acid 
• 221196-01-6 3-chloro-6-phenyl-pyridazin-4-ylamine 

Downstream Products

• 1026565-12-7 (5-amino-6-oxo-3-phenyl-6H-pyridazin-1-yl)-acetic acid ethyl ester 
• 518344-25-7 4,5-diamino-6-phenyl-2H-pyridazin-3-one 
• 881993-34-6 C₂₅H₃₂BrN₃O₇ 
• 350578-58-4 C₂₀H₂₄N₆O₅ 
• 350578-59-5 C₂₀H₂₆N₄O₅ 
• 350578-56-2 C₂₀H₂₄BrN₃O₅ 

Relevant academic research and scientific papers

SUBSTITUTED TRICYCLICS AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Synthesis of pyrido[2,3-d]pyridazines and pyrazino[2,3-d]-pyridazines-novel classes of GABAA receptor benzodiazepine binding site ligands

Novel syntheses of 2,3,8-trisubstituted pyrido[2,3-d]pyridazines and 2,3,5-trisubstituted pyrazino[2,3-d]pyridazines are described. Two complementary routes to pyrido[2,3-d]pyridazines were developed, the first of which began by constructing the pyridine

Pyrazino-pyridazine derivatives as ligands for gaba receptors

A class of pyrazino[2,3-d]pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 5-position, a substituted alkoxy moiety at the 3-position, and a range of substituents at the 2-position, are selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 and/or α5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, ceonvulsions and cognitive disorders.

Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors

The isoxazolo-[3,4-d]-pyridazin-7-(6H)-one (2) and its corresponding open derivatives 5-acetyl-4-amino-(4-nitro)-6-substituted-3(2H)pyridazinones (3, 4) were used as simplified substrates for the synthesis of new aldose reductase inhibitors with respect t